Navigation Links
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Date:7/7/2009

Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control and low incidence of hypoglycemia when used with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a s
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2. Strativas New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
3. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
4. A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis
5. U.S. FDA Accepts Aridol(TM) New Drug Application for Review
6. City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
7. ZyGEM Releases Application Note Showing its DNA Extraction Kits Rapidly Produce High Yields of Quality DNA
8. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
9. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
10. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
11. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... and animal removal company, is happy to announce their recent Quality ... The special designation, awarded by the National Pest Management Association, rewards ... their customers, satisfaction. , ... Houston, TX (PRWEB) September ...
... PAREXEL International,Corporation (Nasdaq: PRXL ), a ... financial guidance for the,first quarter of Fiscal Year ... Fiscal Year, in conjunction with the successful completion ... discussed herein., Josef von Rickenbach, Chairman and ...
... is featured speaker: ,Ion Channel Panels for Safety Assessment ... Drug Discovery, on Tuesday, September 9th at 2:30, ... ion channel-expressing cell lines and services for drug-discovery,and development ... and cell lines in booth 5 at the Ion ...
Cached Biology Technology:Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services 2Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 4PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 5ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5 2ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5 3
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... of the nation,s most enterprising researchers were named ... Pew Charitable Trusts today. The scholarships provide flexible ... perplexing health problems such as diabetes, autism, Parkinson,s ... prestigious community of researchers who have gone on ...
... ILL. --- When you squeeze something, it gets smaller. Unless ... Chicago laboratory, a group of scientists has seemingly defied the ... to make a material expand instead of compress/contract. ... said Karena Chapman, a chemist at the U.S. Department of ...
... a lost fingertip, including the nail, nerves and even bone. ... little as two months, a phenomenon that has remained poorly ... journal Nature , researchers at NYU Langone Medical Center ... genetically engineered mice to document for the first time the ...
Cached Biology News:From autism to diabetes to Parkinson's disease 2From autism to diabetes to Parkinson's disease 3Discovery of new material state counterintuitive to laws of physics 2Fingernails reveal clues to limb regeneration 2
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Pooled normal sreum with 0.1% sodium azide as preservative...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: